Trending Now - Promising New Treatment Offers Hope for Pancreatic Cancer Patients

WHO:

Gizmodo - Revolution Medicines is the company developing the drug daraxonrasib.

STAT - Ben Sasse, a former U.S. senator from Nebraska, is a patient in the clinical trial.

WHAT:

Gizmodo - In a Phase III trial, daraxonrasib almost doubled the survival length of people with advanced pancreatic cancer.

STAT - The trial, RASolute 302, showed that daraxonrasib alone can improve the survival of advanced pancreatic cancer patients to 13.2 months compared to 6.7 months on chemotherapy for second-line therapy.

STAT - Ben Sasse reported a 60% tumor volume reduction and a drop in his CA 19-9 levels from over 8,000 to 374.

WHERE:

STAT - Ben Sasse received treatment at MD Anderson and Memorial Sloan Kettering, two prominent cancer treatment centers in the United States.

WHEN:

STAT - Ben Sasse was diagnosed with metastatic pancreatic cancer in December 2025.

STAT - Sasse began the clinical trial in March 2026.

WHY:

STAT - Ben Sasse chose to enroll in the clinical trial as it was presented as his best option for extending his life beyond the three to four months initially given by doctors.

HOW:

STAT - Sasse learned about the trial through consultations at MD Anderson and Memorial Sloan Kettering, where he was advised to participate in the trial by Dr. Eileen O’Reilly, a leading pancreatic cancer doctor.

(UPDATED April 14, 2026 17:22 UTC)

Revolution Medicines is developing a promising new drug called daraxonrasib, which has shown remarkable results in a Phase III trial for advanced pancreatic cancer. The trial, known as RASolute 302, demonstrated that daraxonrasib can nearly double survival time for patients, with former U.S. senator Ben Sasse reporting a significant tumor volume reduction and a drop in his cancer marker levels after starting treatment at MD Anderson and Memorial Sloan Kettering. Sasse, diagnosed with metastatic pancreatic cancer in December 20th25, enrolled in the trial in March 20th26 after being advised by Dr. Eileen O’Reilly, as it was presented as his best option for extending his life.